Alpa Laboratories Limited
NSE: ALPA BSE: ALPA
Prev Close
109.48
Open Price
110.85
Volume
53,436
Today Low / High
107.52 / 110.85
52 WK Low / High
69.9 / 144.5
Range
103 - 114
Prev Close
109.45
Open Price
109.15
Volume
2,256
Today Low / High
107.95 / 110.7
52 WK Low / High
71 / 144.6
Range
103 - 114
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 108.82 (target range: 103 - 114), reflecting a change of -0.66 (-0.60285%). On the BSE, it is listed at 108.2 (target range: 103 - 114), showing a change of -1.25 (-1.14207%). The stock price is currently in decline on both exchanges, signaling a downtrend. If you're considering investing in this stock, it's important to monitor the situation closely.
Alpa Laboratories Limited Graph
Alpa Laboratories Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Alpa Laboratories Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 108.82, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
Scenario | Price | Target | Range |
---|---|---|---|
Bullish Scenario | 108.20 | 109.28 | 98.35 - 120.21 |
110.36 | 88.29 - 132.44 | ||
111.45 | 78.01 - 144.88 | ||
Bearish Scenario | 108.20 | 107.12 | 96.41 - 117.83 |
106.04 | 84.83 - 127.24 | ||
104.95 | 73.47 - 136.44 |
Overview of Alpa Laboratories Limited
ISIN
INE385I01010
Industry
Drug Manufacturers - Specialty & Generic
Vol.Avg
50,228
Market Cap
2,289,638,092
Last Dividend
0
Official Website
IPO Date
2007-08-06
DCF Diff
58.35
DCF
50
Financial Ratios Every Investor Needs
Annual Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|---|---|
2024-03-31 | 108.74 Cr | 89.85 Cr | 18.89 Cr | 0.1737 | 0.00 Cr | 1.57 Cr | 6.15 Cr | 16.78 Cr | 8.01 | 23.00 Cr | 0.1543 |
2023-03-31 | 92.41 Cr | 61.67 Cr | 30.74 Cr | 0.3327 | 0.00 Cr | 1.10 Cr | 7.34 Cr | 12.58 Cr | 5.98 | 17.44 Cr | 0.1362 |
2022-03-31 | 110.51 Cr | 76.11 Cr | 34.41 Cr | 0.3113 | 0.00 Cr | 1.72 Cr | 9.54 Cr | 14.09 Cr | 6.70 | 21.43 Cr | 0.1275 |
2021-03-31 | 96.41 Cr | 64.76 Cr | 31.66 Cr | 0.3284 | 0.00 Cr | 2.20 Cr | 9.72 Cr | 7.25 Cr | 3.44 | 13.03 Cr | 0.0752 |
2020-03-31 | 84.87 Cr | 55.28 Cr | 29.59 Cr | 0.3487 | 0.00 Cr | 2.08 Cr | 4.52 Cr | 1.85 Cr | 0.88 | 6.24 Cr | 0.0218 |
Annual Financials Balance Sheet
Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-03-31 | 1.71 Cr | 182.37 Cr | 30.46 Cr | 151.9096 Cr | 5.25 Cr | 3.54 Cr | 13.67 Cr | 11.41 Cr | 6.44 Cr | 0.00 Cr | 9.92 Cr | 28.3165 Cr |
2023-03-31 | 8.81 Cr | 167.27 Cr | 32.69 Cr | 134.5775 Cr | 2.30 Cr | -6.51 Cr | 12.64 Cr | 6.96 Cr | 0.00 Cr | 0.00 Cr | -63.72 Cr | 29.6325 Cr |
2022-03-31 | 1.58 Cr | 155.24 Cr | 33.51 Cr | 121.7312 Cr | 5.85 Cr | 4.27 Cr | 15.46 Cr | 9.22 Cr | 0.00 Cr | 0.00 Cr | -61.23 Cr | 31.3834 Cr |
2021-03-31 | 1.80 Cr | 140.37 Cr | 32.73 Cr | 107.6413 Cr | 0.19 Cr | -1.61 Cr | 16.56 Cr | 8.73 Cr | 0.00 Cr | 0.00 Cr | -30.54 Cr | 32.7179 Cr |
2020-03-31 | 4.97 Cr | 121.35 Cr | 20.98 Cr | 100.3725 Cr | 0.41 Cr | -4.56 Cr | 12.55 Cr | 7.22 Cr | 0.00 Cr | 0.00 Cr | -22.01 Cr | 20.7867 Cr |
Annual Financials Cash Flow Statement
Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
---|---|---|---|---|---|---|---|---|---|---|---|
2024-03-31 | 3.6487 Cr | -13.3357 Cr | 2.5832 Cr | -2.7365 Cr | -5.7038 Cr | 3.1101 Cr | -6.3852 Cr | 16.7765 Cr | 2.9424 Cr | 0.0000 Cr | -1.0241 Cr |
2023-03-31 | 8.9044 Cr | 2.1275 Cr | -3.7932 Cr | 7.7784 Cr | 7.2387 Cr | 8.8139 Cr | -1.1260 Cr | 15.6805 Cr | -3.5696 Cr | 0.0000 Cr | 2.8224 Cr |
2022-03-31 | 9.9403 Cr | -15.6096 Cr | 5.4425 Cr | 7.7494 Cr | -8.9348 Cr | 1.5752 Cr | -2.1909 Cr | 19.5601 Cr | 5.6616 Cr | 0.0000 Cr | 1.0962 Cr |
2021-03-31 | -1.7000 Cr | 5.8600 Cr | 0.1900 Cr | -4.9200 Cr | 4.3403 Cr | 10.5100 Cr | -3.2200 Cr | 10.7900 Cr | 0.2700 Cr | 0.0000 Cr | -4.0093 Cr |
2020-03-31 | 17.7820 Cr | -11.1623 Cr | -1.3492 Cr | 15.2367 Cr | 5.2706 Cr | 6.1697 Cr | -2.5453 Cr | 2.9075 Cr | -1.2724 Cr | 0.0000 Cr | 1.4882 Cr |
Quarterly Financial Income Report
Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
---|---|---|---|---|---|---|---|---|---|
2024-12-31 | 26.15 Cr | 16.18 Cr | 9.97 Cr | 0.3813 | 0.19 Cr | 8.90 Cr | 4.23 | 9.54 Cr | 0.3404 |
2024-09-30 | 24.94 Cr | 16.10 Cr | 8.84 Cr | 0.3546 | 2.79 Cr | 7.69 Cr | 3.66 | 10.23 Cr | 0.3082 |
2024-06-30 | 21.44 Cr | 18.89 Cr | 2.55 Cr | 0.1190 | -0.01 Cr | 5.10 Cr | 2.42 | 5.69 Cr | 0.2377 |
2024-03-31 | 23.61 Cr | 16.85 Cr | 6.76 Cr | 0.2864 | 2.98 Cr | 3.54 Cr | 1.71 | 7.49 Cr | 0.1498 |
2023-12-31 | 27.31 Cr | 21.97 Cr | 5.34 Cr | 0.1955 | 1.77 Cr | 4.51 Cr | 2.17 | 5.98 Cr | 0.1651 |
Quarterly Financials Balance Sheet
Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
---|---|---|---|---|---|---|---|---|---|
2024-09-30 | 0.11 Cr | 110.48 Cr | 110.59 Cr | 0.00 Cr | 14.72 Cr | 177.37 Cr | 10.89 Cr | 198.97 Cr | 34.36 Cr |
2024-03-31 | 1.71 Cr | 91.14 Cr | 92.85 Cr | 41.73 Cr | 13.67 Cr | 160.74 Cr | 11.41 Cr | 182.37 Cr | 30.46 Cr |
2023-12-31 | -102.05 Cr | 204.11 Cr | 102.05 Cr | 0.00 Cr | 0.00 Cr | 102.05 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2023-09-30 | 2.41 Cr | 106.14 Cr | 102.05 Cr | 40.19 Cr | 12.60 Cr | 167.74 Cr | 6.93 Cr | 183.90 Cr | 40.58 Cr |
2023-06-30 | -82.18 Cr | 164.36 Cr | 82.18 Cr | 0.00 Cr | 0.00 Cr | 82.18 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Quarterly Financials Cash Flow Statement
Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
---|---|---|---|---|---|---|---|---|---|
2024-03-31 | 3.55 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
2023-12-31 | 4.51 Cr | 1.32 Cr | 0.00 Cr | 0.00 Cr | 1.32 Cr | 3.74 Cr | 2.41 Cr | 0.00 Cr | 1.32 Cr |
2023-09-30 | 5.79 Cr | 0.99 Cr | 0.00 Cr | 0.00 Cr | 0.99 Cr | 2.41 Cr | 1.43 Cr | 0.00 Cr | 0.99 Cr |
2023-06-30 | 3.03 Cr | 0.55 Cr | 0.00 Cr | 0.00 Cr | 0.55 Cr | 9.36 Cr | 8.81 Cr | 0.00 Cr | 0.55 Cr |
2023-03-31 | 4.60 Cr | 1.06 Cr | 0.00 Cr | 0.00 Cr | 1.06 Cr | 8.81 Cr | 7.75 Cr | 0.00 Cr | 1.06 Cr |
Splits History
Date | Label | Split Ratio |
---|---|---|
No split history data available. |
Similar Stocks: Drug Manufacturers - Specialty & Generic
Company Name | Symbol | Price | Market Cap | Volume |
---|---|---|---|---|
Sun Pharmaceutical Industries Limited | SUNPHARMA | ₹1,751.50 | ₹4,202,338,920,000.00 | ₹2,683,738.00 |
Divi's Laboratories Limited | DIVISLAB | ₹5,640.00 | ₹1,497,245,160,000.00 | ₹531,900.00 |
Torrent Pharmaceuticals Limited | TORNTPHARM | ₹3,254.80 | ₹1,101,570,786,000.00 | ₹202,237.00 |
Mankind Pharma Limited | MANKIND | ₹2,581.60 | ₹1,065,112,707,232.00 | ₹489,407.00 |
Dr. Reddy's Laboratories Limited | DRREDDY | ₹1,163.60 | ₹969,410,310,072.00 | ₹2,787,901.00 |
Lupin Limited | LUPIN | ₹1,937.20 | ₹884,457,718,000.00 | ₹1,443,063.00 |
Zydus Lifesciences Limited | ZYDUSLIFE | ₹831.55 | ₹836,730,556,500.00 | ₹4,090,344.00 |
Aurobindo Pharma Limited | AUROPHARMA | ₹1,171.60 | ₹680,467,623,200.00 | ₹769,589.00 |
Alkem Laboratories Limited | ALKEM | ₹4,953.30 | ₹592,241,314,500.00 | ₹45,830.00 |
Glenmark Pharmaceuticals Limited | GLENMARK | ₹1,342.40 | ₹378,809,171,200.00 | ₹613,037.00 |
Ipca Laboratories Limited | IPCALAB | ₹1,404.40 | ₹356,301,897,600.00 | ₹63,964.00 |
Laurus Labs Limited | LAURUSLABS | ₹628.05 | ₹338,677,846,650.00 | ₹1,963,259.00 |
Ajanta Pharma Limited | AJANTPHARM | ₹2,694.60 | ₹336,587,875,200.00 | ₹96,774.00 |
Suven Pharmaceuticals Limited | SUVENPHAR | ₹1,168.10 | ₹297,357,376,500.00 | ₹124,155.00 |
J. B. Chemicals & Pharmaceuticals Limited | JBCHEPHARM | ₹1,646.30 | ₹256,291,045,100.00 | ₹104,543.00 |
Wockhardt Limited | WOCKPHARMA | ₹1,413.80 | ₹229,712,810,200.00 | ₹309,368.00 |
Piramal Enterprises Limited | PEL | ₹995.10 | ₹224,373,157,800.00 | ₹440,877.00 |
AstraZeneca Pharma India Limited | ASTRAZEN | ₹8,746.00 | ₹218,650,000,000.00 | ₹31,887.00 |
Eris Lifesciences Limited | ERIS | ₹1,383.00 | ₹188,313,429,000.00 | ₹41,650.00 |
Alembic Pharmaceuticals Limited | APLLTD | ₹849.90 | ₹167,058,893,700.00 | ₹300,134.00 |
Neuland Laboratories Limited | NEULANDLAB | ₹12,821.00 | ₹164,492,147,900.00 | ₹33,908.00 |
Caplin Point Laboratories Limited | CAPLIPOINT | ₹1,967.10 | ₹149,522,615,070.00 | ₹127,499.00 |
NATCO Pharma Limited | NATCOPHARM | ₹827.60 | ₹148,231,436,000.00 | ₹299,818.00 |
Jubilant Pharmova Limited | JUBLPHARMA | ₹918.95 | ₹146,371,274,950.00 | ₹252,814.00 |
Glenmark Life Sciences Limited | GLS | ₹1,086.00 | ₹133,070,838,000.00 | ₹130,938.00 |
Granules India Limited | GRANULES | ₹467.50 | ₹113,365,945,000.00 | ₹1,134,180.00 |
Procter & Gamble Health Limited | PGHL | ₹5,218.00 | ₹86,615,669,200.00 | ₹2,232.00 |
FDC Limited | FDC | ₹430.45 | ₹70,081,564,500.00 | ₹58,398.00 |
Aarti Pharmalabs Limited | AARTIPHARM | ₹733.60 | ₹66,489,557,232.00 | ₹336,064.00 |
Shilpa Medicare Limited | SHILPAMED | ₹668.50 | ₹65,373,216,650.00 | ₹88,055.00 |
Strides Pharma Science Limited | STAR | ₹653.00 | ₹60,182,243,100.00 | ₹289,176.00 |
Hikal Limited | HIKAL | ₹431.60 | ₹53,216,711,600.00 | ₹794,158.00 |
Innova Captab Limited | INNOVACAP | ₹913.20 | ₹52,257,806,076.00 | ₹59,550.00 |
Sun Pharma Advanced Research Company Limited | SPARC | ₹149.93 | ₹48,655,583,460.00 | ₹540,168.00 |
Unichem Laboratories Limited | UNICHEMLAB | ₹613.95 | ₹43,225,640,910.00 | ₹15,117.00 |
Orchid Pharma Limited | ORCHPHARMA | ₹775.95 | ₹39,355,485,645.00 | ₹55,962.00 |
Sequent Scientific Limited | SEQUENT | ₹147.34 | ₹36,879,496,680.00 | ₹955,155.00 |
RPG Life Sciences Limited | RPGLIFE | ₹2,201.80 | ₹36,415,570,200.00 | ₹6,105.00 |
Gufic Biosciences Limited | GUFICBIO | ₹343.65 | ₹34,460,534,700.00 | ₹25,634.00 |
Aarti Drugs Limited | AARTIDRUGS | ₹357.45 | ₹32,624,461,500.00 | ₹108,626.00 |
Morepen Laboratories Limited | MOREPENLAB | ₹52.36 | ₹28,690,871,440.00 | ₹2,998,041.00 |
Suven Life Sciences Limited | SUVEN | ₹126.32 | ₹27,547,107,680.00 | ₹168,622.00 |
Alembic Limited | ALEMBICLTD | ₹103.97 | ₹26,697,624,436.00 | ₹491,826.00 |
Solara Active Pharma Sciences Limited | SOLARA | ₹523.60 | ₹25,160,550,800.00 | ₹47,862.00 |
Windlas Biotech Limited | WINDLAS | ₹1,084.10 | ₹22,786,697,900.00 | ₹176,971.00 |
Key Executives
Gender: male
Year Born: 1979
Gender: male
Year Born: 1957
Gender: female
Year Born:
Gender: male
Year Born: 1975
Gender: male
Year Born: 1942
Gender: male
Year Born: 1961
Gender: male
Year Born: 1948
FAQs about Alpa Laboratories Limited
The CEO is Mr. Mahendra Singh Chawla.
The current price is ₹108.82.
The range is ₹69.9-144.5.
The market capitalization is ₹228.96 crores.
The P/E ratio is 9.08.
The company operates in the Healthcare sector.
Overview of Alpa Laboratories Limited (ISIN: INE385I01010) is a leading Drug Manufacturers - Specialty & Generic in India. With a market capitalization of ₹228.96 crores and an average daily volume of 50,228 shares, it operates in the Drug Manufacturers - Specialty & Generic. The company last declared a dividend of ₹0.